The study had several limitations, according to the researchers
Oct 9: In a relatively rare move, the FDA went against the recommendation of one of its advisory committees, rejecting a bid by Alnylam to expand Onpattro (patisiran)s label to cardiomyopathy of transthyretin-mediated amyloidosis
Against other weight loss drugs, Semaglutide has been more effective in reducing body weight compared to drugs like orlistat (fat absorption inhibitor), liraglutide (another GLP-1 receptor agonist), and phentermine-topiramate (appetite suppressant and seizure medication combo)
Washout periods for planned conception remain guided by pharmacokinetics and labeling, in the absence of direct clinical evidence
Furthermore, the retrospective nature of the study represents a weakness, as well as not being able to compare our treatment groups due to the basal differences observed between them